Know Your Product
[DOI] [Google Scholar] 8.Vargas-Uricoechea H., Wartofsky L
In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) and Zepbound (15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)
Some people find that taking tirzepatide at night versus morning changes the severity of GI side effects, including constipation
For example, if a patient is experiencing nerve pain, its important to figure out if its coming from a problem in the brain and spinal cord, or if its due to a problem in the nerves throughout the body
Third-Party Consumer Feedback Platforms